03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Long Covid
William "Skip" Pridgen: no photograph is held, so the academic plate is shown instead.
Academic
William "Skip" Pridgen
M.D., Co-Founder and Chief Executive Officer of PridCor Therapeutics
1
0
1
Sept 2026Oct 2026Nov 2026to date
2
press citations on 1 topic since 24 Sept 2026 · last quoted 10 Nov 2026
02 Quoted on · 1 of 29 topics
William "Skip" Pridgen: key facts
- Kind of voice
- Academic
- Role
- M.D., Co-Founder and Chief Executive Officer of PridCor Therapeutics
- Quoted on
- Long Covid
- Tracked press citations
- 2
- Most recently quoted
- 10 Nov 2026
- First quoted
- 24 Sept 2026
04 The signal · where William "Skip" Pridgen sits on long covid
Ranked 21= of 100 voices quoted in the press on long covid, level with 21 others on 2 citations.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=
Dr Charles ShepherdClinicianTrustee and Honorary Medical Adviser, The ME Association9 - 1=Professor Dmitry PshezhetskiyAcademicProfessorial Research Fellow, Norwich Medical School, University of East Anglia9
- 3
Dr. Ewan HunterBusiness leaderChief Data Officer, Oxford BioDynamics Plc6 - 21=James ChalmersAcademicM.D., Ph.D., Rhodes Chair of Experimental Therapeutics and Clinical Pharmacology at the University of Oxford2
- 21=David PutrinoAcademicPhD, director of rehabilitation innovation at the Mount Sinai Health System in New York City2
- 21=William "Skip" PridgenAcademicM.D., Co-Founder and Chief Executive Officer of PridCor Therapeutics2
- 21=Blair GrubbAcademiccardiologist at the University of Toledo Health2
- 21=Dr. Keith RoachClinicianDoctor2
Showing the leaders and the ranks around 21=, of 100 voices · See every voice on the topic →
05 On the record · press
What William "Skip" Pridgen has said
By outlet · linked articles
- wboc.com2
Where William "Skip" Pridgen has been quoted
Verbatim
“Enrolling the first participant is the moment SHIELD becomes real. Our case series was small and open-label. The signal we saw there is exactly what SHIELD is designed to test under blinding and against a placebo arm. People living with Long COVID deserve a rigorous answer.”
“SHIELD is moving from planning to execution. Our case series was small and open-label, and the paper itself concluded that a randomized, placebo-controlled trial had to come next. SHIELD is that trial. It is designed to tell us whether what we observed holds up under blinding and against a placebo arm, and people living with Long COVID deserve that answer.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.